Lotus Pharmaceutical Co (TPE:1795) Cyclically Adjusted Book per Share: NT$52.85 (As of Dec. 2025)


TPE:1795 Lotus Pharmaceutical Co Ltd TPE:1795
76 GF Score
Price NT$209.50
GF Value NT$449.35
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Lotus Pharmaceutical Co Cyclically Adjusted Book per Share?

Lotus Pharmaceutical Co TPE:1795 +1.21% 76 Cyclically Adjusted Book per Share is NT$52.85 as of Dec. 2025. GuruFocus rates TPE:1795 with a GF Score™ of 76/100 and a GF Value™ of NT$449.35 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Lotus Pharmaceutical Co's adjusted book value per share for the three months ended in Dec. 2025 was NT$90.483. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is NT$52.85 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Lotus Pharmaceutical Co's average Cyclically Adjusted Book Growth Rate was 10.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 13.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 14.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Lotus Pharmaceutical Co was 16.80% per year. The lowest was 13.00% per year. And the median was 14.25% per year.

As of today (2026-07-08), Lotus Pharmaceutical Co's current stock price is NT$209.50. Lotus Pharmaceutical Co's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2025 was NT$52.85. Lotus Pharmaceutical Co's Cyclically Adjusted PB Ratio of today is 3.96.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Lotus Pharmaceutical Co was 9.02. The lowest was 1.96. And the median was 4.47.


Lotus Pharmaceutical Co  (TPE:1795) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Lotus Pharmaceutical Co's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=209.50/52.85
=3.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Lotus Pharmaceutical Co was 9.02. The lowest was 1.96. And the median was 4.47.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Lotus Pharmaceutical Co Cyclically Adjusted Book per Share Related Terms


Lotus Pharmaceutical Co Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Lotus Pharmaceutical Co's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lotus Pharmaceutical Co Cyclically Adjusted Book per Share Chart

Lotus Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.00 36.49 42.44 47.69 52.85

Lotus Pharmaceutical Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.69 49.22 50.48 51.83 52.85

TPE:1795 vs ZTS, UTHR: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lotus Pharmaceutical Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lotus Pharmaceutical Co Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lotus Pharmaceutical Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Lotus Pharmaceutical Co's Cyclically Adjusted PB Ratio falls into.


TPE:1795
76GF Score
Lotus Pharmaceutical Co Ltd TPE:1795
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lotus Pharmaceutical Co Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lotus Pharmaceutical Co's adjusted Book Value per Share data for the three months ended in Dec. 2025 was:

Adj_Book= Book Value per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=90.483/324.0540*324.0540
=90.483

Current CPI (Dec. 2025) = 324.0540.

Lotus Pharmaceutical Co Quarterly Data

Book Value per Share CPI Adj_Book
201603 33.069 238.132 45.001
201606 32.954 241.018 44.307
201609 32.993 241.428 44.284
201612 31.213 241.432 41.895
201703 31.407 243.801 41.745
201706 30.332 244.955 40.127
201709 30.603 246.819 40.179
201712 30.419 246.524 39.986
201803 30.358 249.554 39.421
201806 29.945 251.989 38.509
201809 30.415 252.439 39.044
201812 30.334 251.233 39.126
201903 31.292 254.202 39.891
201906 32.728 256.143 41.405
201909 31.495 256.759 39.750
201912 31.741 256.974 40.027
202003 31.265 258.115 39.252
202006 32.192 257.797 40.466
202009 33.664 260.280 41.912
202012 35.644 260.474 44.344
202103 37.101 264.877 45.390
202106 40.619 271.696 48.447
202109 41.325 274.310 48.819
202112 42.207 278.802 49.058
202203 44.105 287.504 49.712
202206 43.356 296.311 47.415
202209 51.299 296.808 56.008
202212 52.923 296.797 57.783
202303 53.739 301.836 57.695
202306 58.860 305.109 62.515
202309 64.074 307.789 67.460
202312 65.542 306.746 69.240
202403 64.865 312.332 67.299
202406 69.722 314.175 71.914
202409 76.291 315.301 78.409
202412 79.821 315.605 81.958
202503 79.898 319.799 80.961
202506 77.800 322.561 78.160
202509 84.708 324.800 84.513
202512 90.483 324.054 90.483

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of NT$52.85 mean?
Lotus Pharmaceutical Co (TPE:1795) has a Cyclically Adjusted Book per Share of NT$52.85 as of Dec. 2025. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Lotus Pharmaceutical Co and its competitors.
Is Lotus Pharmaceutical Co's Cyclically Adjusted Book per Share too high?
Lotus Pharmaceutical Co's current Cyclically Adjusted Book per Share is NT$52.85. Overall, Lotus Pharmaceutical Co has a GF Score™ of 76/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lotus Pharmaceutical Co's Cyclically Adjusted Book per Share compare to ZTS and UTHR?
Lotus Pharmaceutical Co's Cyclically Adjusted Book per Share of NT$52.85 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Lotus Pharmaceutical Co and its competitors. Lotus Pharmaceutical Co's current Cyclically Adjusted Book per Share is NT$52.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lotus Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Lotus Pharmaceutical Co (TPE:1795) is currently considered Possible Value Trap. The stock's GF Value™ is NT$449.35, compared to a current price of NT$209.50 — trading 53.4% below its estimated fair value. The current Cyclically Adjusted Book per Share is NT$52.85. Lotus Pharmaceutical Co's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Lotus Pharmaceutical Co (TPE:1795), the current Cyclically Adjusted Book per Share is NT$52.85 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lotus Pharmaceutical Co (TPE:1795) Overvalued in 2026?

Based on GuruFocus' analysis, Lotus Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$209.50 is trading 53.4% below its estimated GF Value™ of NT$449.35. GuruFocus considers Lotus Pharmaceutical Co to be Possible Value Trap.

Key valuation signals for TPE:1795:

  • Cyclically Adjusted Book per Share: NT$52.85
  • GF Value™: NT$449.35 vs. price of NT$209.50 (53.4% below fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the TPE:1795 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lotus Pharmaceutical Co Business Description

Address Song Ren Road, No. 277, 17th Floor, Xin Yi District, Taipei, TWN, 11046
Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. Along with its subsidiaries, it is engaged in the research and development, manufacturing, and sales of generic and branded pharmaceutical products, as well as consulting services. Its product portfolio comprises biosimilars, generic medicines, branded medicines, and various therapies in its research and development pipeline. The Group offers a differentiated portfolio of pharmaceuticals spanning several therapeutic areas, including oncology and immunology, CNS, women's health, primary care and lifestyle, and nephrology, among others. Geographically, it generates maximum revenue from the United States, and the rest from Taiwan, South Korea, Singapore, and other countries.
76GF Score

Get the complete analysis for TPE:1795

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$209.50
Price
NT$449.35
GF Value